Brief: Akebia Therapeutics Q3 basic EPS USD -0.08
08/11/2023 12:33
Nov 8 (Reuters) - Akebia Therapeutics Q3 operating expenses USD 37.073 million. * Q3 operating income USD -13.036 million * Q3 basic EPS USD -0.08 * Q3 net income USD -14.489 million
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule